Literature DB >> 3365919

Inhibition of desipramine 2-hydroxylation by quinidine and quinine.

E Steiner1, E Dumont, E Spina, R Dahlqvist.   

Abstract

Urinary excretion of desipramine (DMI) and 2-hydroxydesipramine (2-OH-DMI) after single oral doses of 25 mg DMI was investigated in seven rapid and three slow debrisoquin hydroxylators, before and after pretreatment with either quinidine or its diastereoisomer quinine. After treatment with 800 mg quinidine daily for 2 days, excretion of 2-OH-DMI decreased by 96% in rapid hydroxylators and 68% in slow hydroxylators. After treatment with 750 mg quinine/day for 2 days, excretion of 2-OH-DMI in rapid hydroxylators was 54% lower than during the control experiment, whereas in slow hydroxylators no significant changes in the excretion pattern were observed. Unchanged DMI constituted only a minor fraction of recovered drug and no significant changes in its recovery were observed in either phenotypic group after pretreatment with quinidine or quinine. Thus both quinidine and quinine decreased the excretion of 2-OH-DMI. At similar does the effect of quinidine was much stronger than that of quinine, virtually transforming rapid hydroxylators into slow hydroxylators. The mechanism probably involves a stereoselective inhibition of DMI 2-hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3365919     DOI: 10.1038/clpt.1988.76

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  Stereoselective inhibition of renal organic cation transport in human kidney.

Authors:  L T Wong; D D Smyth; D S Sitar
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Nonlinear kinetics of nortriptyline in every day practice.

Authors:  S Vandel; G Bertschy; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.

Authors:  W A Daniel; M Syrek; A Haduch; J Wójcikowski
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.

Authors:  Shanna Babalonis; Aidan J Hampson; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  J Clin Pharmacol       Date:  2015-07-29       Impact factor: 3.126

5.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

Review 7.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

8.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

9.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Authors:  M R Shiran; J Chowdry; A Rostami-Hodjegan; S W Ellis; M S Lennard; M Z Iqbal; O Lagundoye; N Seivewright; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.